Prevalence of Mast Cell Activation Syndrome in Patients With EDS With Digestive Disorders

Inclusion Criteria: * with hypermobile Ehlers Danlos syndrome * with digestive disorders * 14 years of age or older (minimum age for the MOS-SF 36 questionnaire) * able to answer the questionnaires * whose participation in a day hospital at Saint Vincent de Paul dedicated to the assessment of "functional digestive pain" is planned * who do not object to the use of their health data for research purposes Additional criteria for minors : \- No objection to the use of health data for research purposes by parents/guardians Exclusion Criteria: * under guardianship or curatorship * having taken a long-term high-dose antihistamine treatment (H1 or H2) during the last two months, according to the following thresholds : * Desloratadine (\>5 mg/jour) * Bilastine (\>20 mg/jour) * Cetirizine (\>20 mg/jour) * Ebastine (\>10 mg/jour) * Fexofenadine (\>150 mg/jour) * Levocetirizine (\>5 mg/jour) * Loratadine (\>10 mg/jour) * Exocetiridine (5 mg/jour) * Mizolastine (\>10 mg/jour) * Rupatadine (\>10 mg/jour) * Polaramine (\>10 mg/jour) * Oxomemazine (\>2 mg/jour) * Hydroxyzine (\>25 mg/jour) * Doxylamine (\>15 mg/jour) * Cimetidine (\>200 mg/jour) * Patients deprived of liberty, pregnant or nursing women